Clinical Trial Update: Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of MGCD0103 (MG-0103) for relapsed or refractory Hodgkin's lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• MGCD0103 (MG-0103) (MGCD0103)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED